Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2019 Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf Accessed 81, 2019
   Google Scholar
• World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2nd 6 2016 WHO, Geneva.  Available from: https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf Accessed 81, 2019.
   Google Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379–396. doi:10.1001/jama.2018.843130043070
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. European guidelines for treatment of HIV-positive adults in Europe. January 2017, version 8.2. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/hiv.12600 Accessed 81, 2019
   Google Scholar
• Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737–1745. doi:10.1097/QAD.0b013e32834a1dd921716073
   PubMed Web of Science ®Google Scholar
• Kozal MJ, Lupo S, Dejesus E, et al. A nucleoside- and ritonavir sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13(3):119–130. doi:10.1310/hct1303-11922592092
   PubMed Web of Science ®Google Scholar
• Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral naïve adults infected with HIV-1: 96-week results from the NEAT00ANRS143 randomized non-inferiority trial. Lancet. 2013;384(9958):1942–1951. doi:10.1016/S0140-6736(14)61170-3
   Web of Science ®Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infect Dis. 2019;6(3):ofz056. doi:10.1093/ofid/ofz12530895201
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor- related lipodystrophy syndrome. AIDS. 2000;14:F25–F32. doi:10.1097/00002030-200002180-0000110716495
   PubMed Web of Science ®Google Scholar
• Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316. doi:10.1097/00002030-200007070-0000210930144
   PubMed Web of Science ®Google Scholar
• Allavena C, Ferré V, Brunet-François C, et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39:300–306. doi:10.1097/01.qai.0000165914.42827.bb15980689
   PubMed Web of Science ®Google Scholar
• Libre JM, Hung CC, Brinson C, et al. Phase III SWORD 1 & 2: switch to DTG + RPV maintains virologic suppression through 48 weeks [abstract 44LB]. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections 2 13–16; 2017; Seattle.
   Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106. doi:10.1056/NEJMoa07460918480202
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48-week results from the randomized double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–743. doi:10.1016/S0140-6736(12)61853-423306000
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir, lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–1818. doi:10.1056/NEJMoa121554124195548
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48-week results from the randomized open-label phase 3b study. Lancet. 2014;383:2222–2231. doi:10.1016/S0140-6736(14)60084-224698485
   PubMed Web of Science ®Google Scholar
• Cahn P, Andrade-Villanueva J, Arribas J, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48-week results of the randomized, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14(7):572–580. doi:10.1016/S1473-3099(14)70736-424783988
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naıve HIV-infected individuals in three randomized trials. AIDS. 2015;29:167–174. doi:10.1097/QAD.000000000000051925387312
   PubMed Web of Science ®Google Scholar
• Dovato (dolutegravir/lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; 4 2019.
   Google Scholar
• Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016;62:784–791. doi:10.1093/cid/civ98126658053
   PubMed Web of Science ®Google Scholar
• “Dolutegravir.” National center for biotechnology information. PubChem Compound Database, U.S. National Library of Medicine. Available from: pubchem.ncbi.nlm.nih.gov/compound/Dolutegravir Accessed 81st, 2019
   Google Scholar
• PubChem. Dolutegravir. [online]. 2019 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Dolutegravir-sodium Accessed 81, 2019.
   Google Scholar
• Podany AT, Scarsi KK, Fletcher CV, et al. Comparative clinical pharmaco-kinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors. Clin Pharmacokin. 2017;56(1):25–40. doi:10.1007/s40262-016-0424-1
   PubMed Web of Science ®Google Scholar
• Kandel C, Walmsley S. DTG – a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther. 2015;9:3547–3555. doi:10.2147/DDDT.S84850
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Hadzic T, Kashuba AD, et al. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokin. 2013;52(11):981–994. doi:10.1007/s40262-013-0093-2
   PubMed Web of Science ®Google Scholar
• “Lamivudine” National Center for Biotechnology Information. PubChem Compound Database, U.S. National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Lamivudine Accessed 81, 2019
   Google Scholar
• PubChem. Lamivudine. [online]. 2019 Available from: https://pubchem.ncbi.nlm.nih.gov/compound/60825#section=Structures Accessed 81, 2019
   Google Scholar
• Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV working party. N Engl J Med. 1995;333:1662–1669. doi:10.1056/NEJM1995122133325027477218
   PubMed Web of Science ®Google Scholar
• Moore KHP Pharmacokinetics (PK) of lamivudine (3TC) phosphorylation on peripheral blood mammalian cells (PBMC) from HIV-infected patients [abstract]. 12th International Conference on AIDS; June 28–July 3; 1998; Geneva, CH.
   Google Scholar
• Perry CM, Faulds D. Lamivudine: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997;53(4):657–680. doi:10.2165/00003495-199753040-000089098665
   PubMed Web of Science ®Google Scholar
• Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: a randomized controlled comparison with zidovudine monotherapy. JAMA. 1996;276(2):118–125.8656503
   PubMed Web of Science ®Google Scholar
• Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004;2:147–151.15482179
   PubMedGoogle Scholar
• Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol. 2009;83:2038–2043. doi:10.1128/JVI.02154-0819019971
   PubMed Web of Science ®Google Scholar
• Cahn P, Rolon MJ, Figueroa MI, et al. Dolutegravir-Lamivudine as initial therapy in HIV-1 infected ARV-naïve patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir 3TCivudinE) study. J Int AIDS Soc. 2017;20:1. doi:10.7448/IAS.20.01.21678
   Web of Science ®Google Scholar
• Taiwo B, Zheng L, Stefanescu A. et al. ACTG A5353: A pilot study of dolutegravir plus lamivudine for initial treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected participants with HIV-1 RNA <500000 copies/mL. Clin Infect Dis. 2018;66(11):1689–1697. doi:10.1093/cid/cix108329253097
   PubMed Web of Science ®Google Scholar
• Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicenter, double-blind, randomized, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155. doi:10.1016/S0140-6736(18)32462-030420123
   PubMed Web of Science ®Google Scholar
• Faraj A, Agrofoglio LA, Wakefield JK, et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother. 1994;38:2300. doi:10.1128/aac.38.9.21437530932
   PubMed Web of Science ®Google Scholar
• Gao Q, Gu Z, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (–) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother. 1993;37:1390. doi:10.1128/AAC.37.6.13908392313
   PubMed Web of Science ®Google Scholar
• Zash R, Holmes L, Diseko M. et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl Med. 2019;10:1056.
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl/tables.pdf Accessed 81,2019
   Google Scholar
• Gutierrez F, Fulladosa X, Barril G, et al. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16:199–212.25350530
   PubMed Web of Science ®Google Scholar
• Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immuno-deficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994;269:12633.8175673
   PubMed Web of Science ®Google Scholar
• Schinazi RF, Chu CK, Peck A, et al. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 1992;36:672. doi:10.1128/AAC.36.3.6721320365
   PubMed Web of Science ®Google Scholar
• Honkoop P, de Man R, Niester H, et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of Lamivudine. Hepatology. 2000;32(3):635–639. doi:10.1053/jhep.2000.1633310960461
   PubMed Web of Science ®Google Scholar
• Tivicay (dolutegravir) [package insert].Triangle Park, NC; 2018
   Google Scholar
• Epivir (lamivudine) [package insert]. Triangle Park, NC; 2018
   Google Scholar
• Iacobucci G. HIV: dolutegravir should be preferred treatment option in all populations, says WHO. BMJ;2019 l4831. doi:10.1136/bmj.l483131337663
   PubMed Web of Science ®Google Scholar
• Caihol J, Rouyer C, Alloui C, Jeantils V. Dolutegravir and neuropsychiatric adverse events: a continuing debate. AIDS. 2017;31(14):2023–2024. doi:10.1097/QAD.000000000000159628857781
   PubMed Web of Science ®Google Scholar
• Doyle T, Dunne DT, Ceccherini-Silberstein F, et al. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 2015;70:3080–3086. doi:10.1093/jac/dkv24326311843
   PubMed Web of Science ®Google Scholar